Low-grade gliomas with duplication of FGFR1 TKD or MYB overexpression show activation of the MAPK/ERK and PI3K pathways, showing expression profiles similar to those of pilocytic astrocytomas with BRAF fusions and suggest that these pathways may represent potentially important therapeutic targets [129]. The gene discussed is FGFR1; the disease is glioma.